Rituximab in the treatment of non-Hodgkin's lymphoma-a critical evaluation of randomized controlled trials

Expert Opinion on Biological Therapy

Volumn 13, Issue 5, 2013, Pages 803-811

  Griffin, Morag Meriel ^a   Morley, Nick ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Diffuse large B cell lymphoma; Follicular lymphoma; Mantle cell lymphoma; Rituximab

Indexed keywords

ANTIHISTAMINIC AGENT; HYDROCORTISONE; PARACETAMOL; RITUXIMAB;

ABDOMINAL PAIN; CANCER CHEMOTHERAPY; CANCER RECURRENCE; FLUSHING; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; LARGE CELL LYMPHOMA; MAINTENANCE THERAPY; MEMORY CELL; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CARCINOMA, PAPILLARY, FOLLICULAR; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL; LYMPHOMA, MANTLE-CELL; LYMPHOMA, NON-HODGKIN; MAINTENANCE CHEMOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE;

EID: 84876013705     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.786698     Document Type: Review

References (46)

1. Hoffbrand A, Catovsky D, Tuddenham E, et al. Postgraduate haematology. 6th edition. Wiley-Blackell, UK; 2011
2. Grillo-Lopez AJ, White C, Dallaire B, et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol 2000;1:1-9
3. Teeling J, Mackus J, Wiegman L, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177(1):362-71
4. Weiner G. Rituximab: mechanism of action. Semin Hematol 2010;47(2):115-23
5. Bedognetti D, Zoppoli G, Massucco C, et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-hodgkin's lymphoma patients treated with rituximab-containing regimens. J Immunol 2011;186(10):6044-55
6. Straus DJ, Huang J, Testa MA, et al. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142-low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colonystimulating factor. National Institute of Allergy and Infectious Diseases. J Clin Oncol 1998;16(11):3601-6 . Response of HIV patients with NHL to treatment.
7. Lim ST, Karim R, Tulpule A, et al. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. Clin Oncol 2005;23(33):8477-82 . Response of HIV patients with NHL to treatment.
8. Weiss R, Mitrou P, Arasteh K, et al. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival-results of the German multicenter trial. Cancer 2006;106(7):1560-8 . Response of HIV patients with NHL to treatment.
9. Lim ST, Karim R, Tulpule A, et al. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. Clin Oncol 2005;23(33):8477-82 . Response of HIV patients with NHL to treatment.
10. Carson K, Evens A, Richey E, et al. Progressive multifocal leukoencephalopathy after rituximab in HIV negative patients: a report of 57 cases from the Research on adverse drug events and reports project. Blood 2009;113(20):4834-40
11. Berger Jr. The basis for modelling progressive multifocal leukoencephalopathy pathogenesis. Curr Opin Neurol 2011;24(3):262-7
12. Available from: http://www. cancerresearchuk.org/
13. Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007;110(2):695-708
14. Pfreundschuh M, Kuhnt E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011;12(11):1013-22
15. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH- 98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010;116(12):2040-5
16. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of Bi-weekly CHOP 14 with or without rituximab in elderly patients with aggressive CD20+ B-Cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9(2):105-16
17. Habermann T, Weller EA, Morrison V, et al. Rituximab-CHOP versus CHOP alone or with maintenance Rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24(19):3121-7 . Clinical trial of Rituximab use in DLBCL.
18. Vellenga E, van Putten WL, van 't Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20 +NHL: a prospective randomized HOVON trial. Blood 2008;111(2):537-43 . Hovon Clinical trial of treatment of relapsed DLBCL.
19. Crump M, Kuruvilla J, Couban S, et al. Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12. ASH 2012 abstract 745 . Phase 3 clinical trial of treatment of relapsed DLBCL.
20. Gisselbrecht C, Glass B, Mounier N, et al. B-cell lymphoma in the rituximab era. Clin Oncol 2010;28(27):4184-90
21. Gisselbrecht C, Schmitz N, Mounier N, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. JCO 2012;30(36):4462-9
22. Ardeshna KM, Smith P, Norton A, et al. British National Lymphoma Investigation. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003;362(9383):516-22 . Clinical trial studying the use of watch and wait treatment of NHL.
23. Ardeshna K, Smith P, Qian W, et al. An Intergroup randomised trial of Rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis; ASH abstract presented Dec 2010; https://ash.confex. com/ash/2010/webprogram/Paper27692. html . Clinical trial studying the use of watch and wait treatment of NHL.
24. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first line treatment for advanced follicular lymphoma. Blood 2005;105(4):1417-23
25. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. Clin Oncol 2008;26(28):4579-86
26. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106(12):3725-32
27. Rummel M, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. ASCO abstract; 2012
28. Salles G, Seymour J, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a Phase III, randomised controlled trial. Lancet 2011;377(9759):42-51
29. Ghielmini M, Schmitz S, Cogliatti S, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly - 4 schedule. Blood 2004;103(12):4416-23
30. Hochster H, Weller E, Gascoyne R, et al. Maintenance Rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized Phase III ECOG1496 study. J Clin Oncol 2009;27(10):1607-14
31. Hornberger J, Chien R, Friedmann M, et al. Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy (abstract). Leuk Lymphoma 2012;53(12):2371-7
32. Available from: http://guidance.nice.org. uk/TA226
33. Van Oers M, Klasa R, Marcus R, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized Phase III intergroup trial. Blood 2006;108(10):3295-301
34. Forstpointner R, Dreyling M, Repp R, et al. The addition of Rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphoma: results of a prospective randomised study of the German low grade lymphoma study group. Blood 2004;104(10):3064-71 . German Low Grade Lymphoma Study Group clinical trial of Rituximab use in mantel cell lymphoma.
35. Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2011;103(23):1799-806
36. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108(13):4003-8
37. van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-hodgkin's lymphoma: long-term outcome of the EORTC 20981 Phase III randomized intergroup study. J Clin Oncol 2010;28(17):2853-8 . Phase 3 Intergroup clinical trial of Rituximab maintenance in Follicular lymphoma.
38. Robak T. Rituximab for chronic lymphocytic Leukemia. Expert Opin Biol Ther 2012;12(4):503-15 . Review on the use of Rituximab in CLL.
39. Available from: https://ash.confex.com/ ash/2011/webprogram/Paper40796. html
40. Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012;367(6):520-31
41. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23(9):1984-92
42. Schulz H, Bohlius J, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007;99(9):706-14
43. Zucca E, Conconi A, Laszlo D, et al. Addition of Rituximab to Chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol 2013;31(5):565-72
44. Barnes J, LaCasce A, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol 2011;22:1859-64
45. Robak T. GA-101, a third-generation, humanized and glyco-engineered anti- CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs 2009;10(6):588-96
46. McLaughlin P, Grillo-Lo?pez AJ, Link BK, et al. Rituximab chimeric anti- CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16(8):2825-33